Company Encyclopedia
View More
name
Immuneering
IMRX.US
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
1.912 T
IMRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026

    Immuneering Corp. announced plans to initiate a Phase 3 trial of Atebimetinib for metastatic pancreatic cancer in mid-2026. The trial, named MAPKeeper 301, will involve 510 patients and compare Atebimetinib with modified gemcitabine and nab-paclitaxel against the standard treatment. The FDA and European Medicines Agency have aligned on the trial's design and endpoints. Immuneering will also update on Phase 2a trial results soon. Additionally, Immuneering will join the Nasdaq Biotechnology Index in December 2025.

    rttnews·
    US
    IMRX
    -0.35%
    rttnews·
    US
    IMRX
    -0.35%

    Immuneering progresses to dosing first patient in Phase 3 Atebimetinib trial for metastatic pancreatic cancer with FDA and EMA approval.

    Immuneering is moving forward in its Phase 3 atebimetinib trial and is on track to dose the first patient. The company has secured alignment with both the FDA and EMA for this significant milestone. This progress marks a key step in the development of atebimetinib and signifies the company's dedication to advancing treatment options in the medical field.

    Unusual Whales·
    US
    IMRX
    -0.35%
    Unusual Whales·
    US
    IMRX
    -0.35%

    Immuneering Corporation joins Nasdaq Biotechnology Index

    Immuneering Corporation will be added to the Nasdaq Biotechnology Index (NBI) effective December 22, 2025, following the annual evaluation of the NBI. This inclusion requires meeting criteria such as minimum market capitalization and trading volume. The original content was published by Immuneering Corporation via GlobeNewswire on December 16, 2025.

    Reuters·
    US
    IMRX
    -0.35%
    Reuters·
    US
    IMRX
    -0.35%

    Platform Oncology Technologies Drive Multi-Indication Treatment Expansion

    Oncolytics Biotech Inc. has secured FDA alignment for its Phase 3 study design of pelareorep in metastatic pancreatic cancer, aiming to launch the first immunotherapy registration trial for this disease. The trial will test chemotherapy alone, with pelareorep, and with a checkpoint inhibitor, focusing on overall survival. Pelareorep holds Fast Track and Orphan Drug designations, promising expedited review. The company is advancing its platform potential across gastrointestinal tumors, with promising data in anal and pancreatic cancers.

    Baystreet·
    US
    ONCY
    0.00%
    Baystreet·
    US
    ONCY
    0.00%

    Immuneering Corporation to Present at Piper Sandler Annual Healthcare Conference

    Immuneering Corporation will present at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 4, 2025. The presentation by CEO Ben Zeskind and other executives will be webcast live and archived on the company's Investor Relations website.

    Reuters·
    US
    IMRX
    -0.35%
    Reuters·
    US
    IMRX
    -0.35%
    © 2025 Longbridge｜Disclaimer